NuVasive Company Profile (NASDAQ:NUVA)

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive, Inc. (NASDAQ:NUVA) issued its earnings results on Thursday, July, 27th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.02. The company earned $260.60 million during the quarter, compared to analysts' expectations of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 EPS. View NuVasive's Earnings History.

NuVasive is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for NuVasive.

NuVasive issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $2.00 for the period, compared to the Thomson Reuters consensus estimate of $2.01. The company issued revenue guidance of $1.065 billion, compared to the consensus revenue estimate of $1.07 billion.

14 analysts have issued 12 month price objectives for NuVasive's shares. Their forecasts range from $60.00 to $90.00. On average, they expect NuVasive's share price to reach $75.25 in the next twelve months. View Analyst Ratings for NuVasive.

Here are some recent quotes from research analysts about NuVasive stock:

• 1. According to Zacks Investment Research, "NuVasive’s second-quarter 2017 performance was mixed with the bottom line beating the estimates and sales missing the mark. However, year-over-year, revenue growth was solid, led by robust performance in the international market on above-market growth across all geographies. Notably, over the recent past, the company has demonstrated steady year-over-year improvement on the top-line front on account of strong procedural growth in the U.S. as well as internationally. We are optimistic about the company’s recent progress in development of technologies and services for spine surgery. On the flip side, over the last three months, NuVasive has been trading below the broader industry. Further, currency headwind, pricing and reimbursement issues along with a competitive landscape are major downsides. Also, the company’s low-margin Biotronic business impacted the second quarter’s performance." (7/31/2017)
• 2. Needham & Company LLC analysts commented, "NUVA’s 2Q17 revenue missed and EPS beat consensus and management maintained its 2017 guidance. Pro forma revenue growth slowed to 5% in 2Q17 from 6% in 1Q17 as biologics sales continued to decline and operational challenges arose from the relocation of a neuromonitoring billing and collection department. NUVA’s operating margin beat consensus and increased 40 bps Y/Y. Despite NUVA’s slower revenue growth, management still expects revenue growth to accelerate in 2H17 given easier comps, new products, new customer wins, and new sales reps coming off non-competes." (7/28/2017)
• 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)
• 4. UBS AG analysts commented, "The company's long-term operating margin goal of 25% was a key topic of discussion last week when we hosted NUVA for investor meetings. Management laid out a clear pathway to 25% operating margins (from 16.1% currently), which included: 1) 400 bps from in-source manufacturing; 2) 400 bps from asset efficiencies; 3) 400 bps from OUS scalability; and 4) 200 bps from sales force efficiencies, offset by 500 bps of R&D investment and pricing headwinds. We reiterate our Buy rating on NUVA and $82 price target and expect consistent execution and margin improvements to drive the stock higher." (3/20/2017)

Some companies that are related to NuVasive include Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), DexCom (DXCM), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), CONMED Corporation (CNMD), MiMedx Group (MDXG), Asante Solutions (PUMP), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Cardiovascular Systems (CSII) and K2M Group Holdings (KTWO).

NuVasive's management team includes the folowing people:

• Gregory T. Lucier, Chairman of the Board, Chief Executive Officer
• Rajesh J. Asarpota, Chief Financial Officer, Executive Vice President
• Joan B. Stafslien, Executive Vice President, General Counsel, Corporate Secretary
• Carol A. Cox, Executive Vice President - External Affairs and Corporate Marketing
• Peter Michael Leddy Ph.D., Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications
• Matthew W. Link, Executive Vice President - Strategy, Technology and Corporate Development
• Stephen Rozow, - Global Process Transformation
• Vickie L. Capps, Independent Director
• Peter C. Farrell Ph.D., Independent Director
• Robert F. Friel, Independent Director

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NuVasive stock can currently be purchased for approximately $54.18.